Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 11, 2014

View Archived Issues

In vivo data for the novel anti-Abeta-oligomer antibody ACU-3B3

Phase II results presented for clazakizumab in patients with active psoriatic arthritis

Endo acquires rights to Natesto testosterone nasal gel

OncoSec Medical confirms phase II trial of ImmunoPulse in head and neck cancer

Zymeworks and Merck & Co. expand bispecific antibody collaboration

MIPS, Monash University and Takeda form strategic research alliance in gastroenterology

Calithera licenses Mars Symbioscience's arginase inhibitors

La Jolla Pharmaceutical and George Washington University sign license agreement relating to LJPC-501

Ono Pharmaceutical presents a novel dual Axl/Mer inhibitor, ONO-9330547

Spark Therapeutics and Pfizer establish gene therapy collaboration in hemophilia B

Bayer and DNDi sign agreement to develop oral drug for river blindness

Alize Pharma reports phase I findings on AZP-531

Myelo-001 for the prevention of chemotherapy-induced myelosuppression

Spanish researchers report development of neuroprotective steroidal nitrones

Roche researchers prepare and test CYP11B2 inhibitors

Chinese institute patents new antiviral compounds

Reslizumab improves quality of life of asthma patients with elevated eosinophils

Luoda Biosciences synthesizes novel kinase inhibitors

FDA approves nine-valent HPV vaccine Gardasil 9

Immunovaccine receives FDA fast track designation for DPX-Survivac

Eculizumab receives orphan drug designation in Japan for myasthenia gravis

FDA grants orphan drug designation to rNAPc2 for Ebola

Preclinical studies show promising results on APG-1252 as a novel Bcl-2/Bcl-xL inhibitor

Ono, BMS and Kyowa Hakko Kirin to conduct combination study of Opdivo

U.K. researchers gain access to 68 deprioritized compounds under MRC program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...